Compare LCNB & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | ELDN |
|---|---|---|
| Founded | 1877 | 2004 |
| Country | United States | United States |
| Employees | N/A | 33 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.7M | 235.1M |
| IPO Year | 1999 | 2014 |
| Metric | LCNB | ELDN |
|---|---|---|
| Price | $16.95 | $3.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 29.1K | ★ 1.3M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | ★ 68.04 | 30.67 |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $6,445,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $10.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.56 | $1.35 |
| 52 Week High | $17.89 | $4.60 |
| Indicator | LCNB | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 62.62 | 59.62 |
| Support Level | $17.08 | $2.45 |
| Resistance Level | $17.79 | $3.17 |
| Average True Range (ATR) | 0.41 | 0.20 |
| MACD | 0.21 | -0.01 |
| Stochastic Oscillator | 89.43 | 70.00 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.